Skip to content
Peptideworth
Menu

Peptide guide

BPC-157: What the Evidence Actually Shows

Also called Body Protection Compound-157, PL 14736, Pentadecapeptide BPC 157

BPC-157 is one of the most-searched peptides on the market, and one of the least tested in people. The healing claims come from a large, fairly consistent body of rodent research. What follows that research into human use is a regulatory grey zone, not a clinical trial. Here is what the animal data actually shows, what is proposed to explain it, and what a reader should not assume from either.

By Grant Delaney, Research Editor

BPC-157

Compounding restricted
Animal only

Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

What it is
BPC-157 is a synthetic 15-amino-acid peptide built to match a fragment of a protein found in human gastric juice. It is not extracted from anything — what ships from a research-chemical seller is a lab-synthesized copy of that sequence, sold as an injectable or oral solution.1
Mechanism
Rodent studies propose that BPC-157 promotes new blood vessel growth toward damaged tissue and interacts with several growth-factor and nitric-oxide signaling pathways involved in wound repair. That mechanism is what the tendon-, muscle-, and gut-healing results are attributed to, though the exact receptor it acts through has not been settled.1,2
What the trials found
A 2019 review of the musculoskeletal literature found BPC-157 accelerated healing across dozens of rodent tendon, ligament, and muscle-injury experiments, with a similarly consistent pattern in earlier rat models of gut ulceration. Every one of those experiments was conducted in animals — the review identified no completed randomized controlled trial testing BPC-157 against an outcome in a person.2
The catch
The entire healing story is built on rodent data. Nothing published shows BPC-157 heals a tendon, a muscle, or a gut lesion in a human being, and a 2026 review of unapproved peptide therapies groups it with compounds sold direct to patients without the human safety or efficacy data a real drug approval requires. It is also not on the FDA's list of bulk substances a compounding pharmacy may legally use, so a compliant pharmacy will not sell it — what circulates is unregulated research-chemical stock, not a verified pharmaceutical product.
Dosing evidence
There is no human dose-ranging or pharmacokinetic study to derive a dose from. The milligram amounts and injection schedules circulating on forums and seller sites are scaled down from rodent doses by body weight, which is not how a human dose normally gets established, and none of those extrapolated doses has been tested against an outcome in a person.1
Safety and side effects
Human safety data is thin. The 2026 review of unapproved peptide therapies lists BPC-157 among compounds with favorable animal safety signals but little controlled human safety data, and notes that peptides sold in this category typically carry no batch-purity verification of the kind a pharmaceutical product would.3

Under active FDA restriction — compliant pharmacies decline to sell it.

How to read the evidence meter

Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.

  1. AnecdotalUser reports and forum consensus. No controlled data.
  2. Animal onlyRodent or cell studies. Nothing published in humans.
  3. Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
  4. Randomized trialsRandomized controlled trials in humans, at scale.

Why "from gastric juice" is misleading

BPC-157 is routinely described as derived from a protein in human gastric juice, which makes it sound like a digestive compound your body already produces. What is actually sold is a synthetic peptide built to that amino-acid sequence in a lab — a stomach has never produced a vial of it 1.

What the animal literature actually supports

The rodent results are real and reasonably consistent: across tendon, ligament, muscle, and gut-injury models, BPC-157 shows up as accelerating healing compared to untreated controls 2. That is a genuine, replicated finding. It is also the ceiling of what has been shown — extending a rodent healing result to a person is an assumption, not a conclusion the studies themselves make.

Where the regulatory status leaves a buyer

BPC-157 has not been approved by the FDA as a drug, and it is not on the FDA's list of bulk substances that compounding pharmacies may legally use under Section 503A. A pharmacy trying to stay compliant will decline to sell it. What is available instead is labeled for research use, sold without the purity verification a real medicine carries, and reviewed alongside the rest of that category as running ahead of its human evidence 3.

Frequently asked questions

Has BPC-157 been tested in humans?

Not in a completed randomized controlled trial. The healing effects it is sold for — tendon, ligament, muscle, and gut repair — come entirely from rodent studies. No published human trial has measured whether it produces the same result in a person.

Is BPC-157 legal to buy?

It is not FDA-approved as a drug, and it is not on the FDA's list of substances a compounding pharmacy may legally use, so a compliant pharmacy will not sell it to you. It is sold instead as a research chemical, which is a legal category describing what a seller may ship without a prescription — not a safety or quality standard.

What dose of BPC-157 is effective?

There is no human dosing study to answer that from. Doses seen online are scaled down from rodent studies by body weight, which has never been validated as a way to dose a person, and no such dose has been tested against a human outcome.

References

  1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). https://pubmed.ncbi.nlm.nih.gov/40005999/
  2. Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. https://pubmed.ncbi.nlm.nih.gov/30915550/
  3. Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.